Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
01/19/2021 01/20/2021 01/21/2021 01/22/2021 01/25/2021 Date
5762 5573 5660 5619 5649 Last
1430400 2345700 1915700 1349600 1083900 Volume
+0.19% -3.28% +1.56% -0.72% +0.53% Change
Financials
Sales 2020 768 B 7 395 M 7 395 M
Net income 2020 219 B 2 110 M 2 110 M
Net cash position 2020 410 B 3 951 M 3 951 M
P/E ratio 2020 42,6x
Yield 2020 0,94%
Sales 2021 838 B 8 073 M 8 073 M
Net income 2021 255 B 2 457 M 2 457 M
Net cash position 2021 510 B 4 914 M 4 914 M
P/E ratio 2021 36,8x
Yield 2021 1,15%
Capitalization 9 286 B 89 482 M 89 433 M
EV / Sales 2020 11,6x
EV / Sales 2021 10,5x
Nbr of Employees 7 394
Free-Float 37,7%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
Sector
Pharmaceuticals
Calendar
02/04 | 03:00amEarnings Release
More about the company
Notations Surperformance© of Chugai Pharmaceutical Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD.
05:53aCHUGAI PHARMACEUTICAL : Obtains Approval for Expanded Use of FoundationOne CDx C..
AQ
05:53aCHUGAI PHARMACEUTICAL : Dissolution of Forerunner Pharma Research
AQ
01/25CHUGAI PHARMACEUTICAL : and Taisho Terminate the Co-Marketing Agreement of Ediro..
AQ
01/19CHUGAI PHARMACEUTICAL : Supports the Japan Climate Initiative's Calling to Raise..
AQ
01/13CHUGAI PHARMACEUTICAL : Conducts Digital Transformation in Manufacturing with IB..
AQ
01/12Japanese Shares Close Higher on Positive News About COVID-19 Treatment, Econo..
MT
01/11Drug makers help Nikkei scale fresh 3-decade high
RE
2020Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic ..
AQ
2020CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2020CHUGAI PHARMACEUTICAL THE : Launch of Chugai's New TV Commercial Featuring Erika..
AQ
2020PRESS RELEASE : European Commission approves Roche's Phesgo (fixed-dose combinat..
DJ
2020CHUGAI PHARMACEUTICAL : Osteoporosis Agent Edirol Obtains Regulatory Approval in..
AQ
2020CHUGAI PHARMACEUTICAL : in-licenses Antibody Cocktail for COVID-19 from Roche
AQ
2020CHUGAI PHARMACEUTICAL : Enspryng Approved in Taiwan as First Approved Medicine f..
BU
2020ROCHE : New follow-up phase III data reinforce the long-term benefit of Roche's ..
AQ
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.
01/12TOKYO STOCK EXCHANGE : Borsa Tokyo, nuovo massimo da 30 anni, farmaceutici in ra..
01/12BOURSES ASIATIQUES : les places chinoises cartonnent, Tokyo atone
01/12MÄRKTE ASIEN/Uneinheitlich - Schanghai-Composite auf Fünfjahreshoch
01/12Tokyo a fait quasiment du surplace
01/12MÄRKTE ASIEN/Uneinheitlich - Kospi mit Gewinnmitnahmen sehr schwach
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Stock Trading Strategies
CHUGAI PHARMACEUTICAL CO., LTD. - 2020
The trend should regain control
BUY
More Stock Trading Analysis
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 5 078,18 JPY
Last Close Price 5 649,00 JPY
Spread / Highest target 15,1%
Spread / Average Target -10,1%
Spread / Lowest Target -27,4%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.2.65%89 482
JOHNSON & JOHNSON5.46%436 949
ROCHE HOLDING AG3.82%309 894
NOVARTIS AG2.96%220 401
PFIZER INC.1.28%207 217
MERCK & CO., INC.-0.79%205 312